SAN DIEGO, CA — May 27, 2026 — SeekIn Inc. (“SeekIn”), a leader in next-generation sequencing (NGS)-based diagnostics and multi-cancer early detection (MCED), today announced that seven abstracts have been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago, USA.
The presentations showcase SeekIn’s expanding portfolio across hematologic malignancies, transplant monitoring, and cancer screening, including novel applications of shallow whole-genome sequencing (sWGS), AI-driven risk stratification, and next-generation MCED assays.
“We are excited to present a broad set of data at ASCO this year, spanning both clinical diagnostics and population-scale screening approaches,” said Dr. Mao Mao, Founder & CEO of SeekIn. “These studies underscore our commitment to advancing precision oncology through innovative, scalable technologies that improve detection, risk assessment, and patient outcomes.”
Hematologic Malignancies and Transplant Monitoring
SeekIn will present three studies focused on improving diagnostic resolution and disease monitoring in hematologic cancers (Session Type/Title: Poster Session - Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant):
- MSNPseq: An NGS-based assay for chimerism detection and risk assessment in allogeneic hematopoietic stem cell transplantation (Abstract #6557; Poster Board 350; June 1, 9:00 AM–12:00 PM CDT).
- Impact of shallow whole genome sequencing on diagnostic yield and prognostic precision in myelodysplastic syndromes (Abstract #6567; Poster Board 360; June 1, 9:00 AM–12:00 PM CDT).
- Copy number aberration profiling using sWGS-based LeukoPrint in multiple myeloma (Abstract #7554; Poster Board 433; June 1, 9:00 AM–12:00 PM CDT).
These studies highlight the utility of sWGS and NGS-based approaches to enhance cytogenetic profiling, improve prognostic stratification, and support post-transplant monitoring.
Cancer Screening, Health Economics, and AI-Driven Risk Stratification
Four additional presentations focus on optimizing cancer screening strategies and improving the efficiency and cost-effectiveness of early detection (Session Type/Title: Poster Session - Prevention, Risk Reduction, and Genetics):
- Integrating multi-cancer early detection into U.S. screening programs: A cost-effectiveness modeling study (Abstract #10523; Poster Board 484; June 1, 1:30 PM–4:30 PM CDT).
- Cost-effective colorectal cancer screening in the United States: Comparative analyses of four molecular tests (Abstract #10525; Poster Board 486; June 1, 1:30 PM–4:30 PM CDT).
- Impact of AI-based risk stratification integrating routine laboratory data with age on screening volume and MCED yield (Abstract #10538; Poster Board 499; June 1, 1:30 PM–4:30 PM CDT).
- Oncoseek 2.0: An updated blood-based assay for multi-cancer early detection (Abstract #10551; Poster Board 512; June 1, 1:30 PM–4:30 PM CDT).
Together, these studies demonstrate SeekIn’s integrated approach to early cancer detection, combining molecular diagnostics, artificial intelligence, and health economic modeling to enable more targeted and scalable screening strategies.
Attendees can visit SeekIn posters during the scheduled sessions on June 1 to learn more about these findings.